Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JUNE 2012. Refer to TA259: Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | abiraterone (Zytiga®) | ||
| Formulation | 250 mg tablet | ||
| Reference number | 3 | ||
| Indication | In combination with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen |
||
| Company | Janssen-Cilag Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 0612 | ||
| NMG meeting date | 04/01/2012 | ||
| AWMSG meeting date | 08/02/2012 | ||
| Ratification by Welsh Government | 17/02/2012 | ||
| Date of issue | 17/02/2012 | ||
| NICE guidance | TA259: Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (external website - opens in new window) |
||
| Commercial arrangement | WPAS | ||